- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Size alone should not determine biopsy decision, RSNA study finds
Radiologists will often not biopsy small lesions because they assume the lesions are benign. But the decision to do so could mean missing malignant cases, according to a scientific session presented Sunday at the RSNA 2009 meeting.
Radiologists will often not biopsy small lesions because they assume the lesions are benign. But the decision to do so could mean missing malignant cases, according to a scientific session presented Sunday at the RSNA 2009 meeting.
Previously published literature shows a low malignancy rate for small MRI-detected masses, but a new study presented by Dr. Meera Sekar, a radiologist in Jamaica Plain, MA, shows even small lesions can be malignant.
In the study, Sekar and colleagues looked at 68 masses detected on MRI. Of all the masses, 36 were 5 mm and 32 were 3 to 4 mm. Biopsy revealed malignancy in 15 masses, for an overall malignancy rate of 22%. Of all the masses less than 5 mm, nine were malignant.
The decision to biopsy lesions less than 5 mm in size detected via MRI should be made based on MRI features and patient risk factors, Sekar said.
"No difference in proportion of malignancies was found based on shape or margins," she said.
However, there was a higher proportion of malignancies in patients who had MR for follow-up of a previous MRI finding and those with washout kinetics, she said.
"Radiologists should take the small lesions seriously," said Dr. Elizabeth Morris, moderator of the session.
Lesions less than 5 mm are not always benign; cancers have to grow and their size can start at something as small as 5 mm, said Morris, director of breast MRI and breast imaging research at Memorial Sloan-Kettering Cancer Center in New York.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
